The collectin SP-A and its trimeric recombinant fragment protect alveolar epithelial cells from the cytotoxic and proinflammatory effects of human cathelicidin

P2X7 channel alveolar epithelial cells antimicrobial activity cathelicidin LL-37 collectin SP-A cytotoxicity inflammation trimeric recombinant fragment

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 14 07 2022
accepted: 08 08 2022
entrez: 15 9 2022
pubmed: 16 9 2022
medline: 17 9 2022
Statut: epublish

Résumé

Human cathelicidin (LL-37) is a defense peptide with antimicrobial activity against various pathogens. However, LL-37 can also trigger tissue injury by binding to host cell membranes. The cytotoxic effects of LL-37 may be especially relevant in chronic respiratory diseases characterized by increased LL-37. The aim of this study was to investigate whether the human collectin SP-A and a trimeric recombinant fragment thereof (rfhSP-A) can regulate the activities of LL-37. To this end, we studied the interaction of LL-37 with SP-A and rfhSP-A by intrinsic fluorescence, dynamic light scattering, and circular dichroism, as well as the effects of these proteins on the antimicrobial and cytotoxic activities of LL-37. Both SP-A and rfhSP-A bound LL-37 with high affinity at physiological ionic strength (

Identifiants

pubmed: 36105805
doi: 10.3389/fimmu.2022.994328
pmc: PMC9464622
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antimicrobial Cationic Peptides 0
Collectins 0
Cathelicidins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

994328

Informations de copyright

Copyright © 2022 de Tapia, García-Fojeda, Kronqvist, Johansson and Casals.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Immunol. 2018 Sep 03;9:1939
pubmed: 30233570
Methods Mol Biol. 2004;261:55-78
pubmed: 15064449
Biochem J. 2007 Sep 15;406(3):479-89
pubmed: 17542781
Sci Rep. 2016 Sep 14;6:32948
pubmed: 27624595
J Immunol. 1999 Jul 1;163(1):387-95
pubmed: 10384140
Biochemistry. 2003 Aug 19;42(32):9532-42
pubmed: 12911295
Respir Res. 2020 Jul 3;21(1):170
pubmed: 32620122
Antimicrob Agents Chemother. 2012 Feb;56(2):845-56
pubmed: 22083479
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8898-903
pubmed: 12855765
FASEB J. 2010 Oct;24(10):3662-73
pubmed: 20484671
Biochem Biophys Res Commun. 2017 Nov 4;493(1):71-76
pubmed: 28919413
Nat Rev Immunol. 2005 Jan;5(1):58-68
pubmed: 15630429
J Clin Cell Immunol. 2018;9(4):
pubmed: 30123671
Expert Opin Investig Drugs. 2011 Jul;20(7):897-915
pubmed: 21510825
JCI Insight. 2021 Feb 8;6(3):
pubmed: 33554955
Immunobiology. 2017 Feb;222(2):111-118
pubmed: 27793398
Front Immunol. 2022 Apr 04;13:860262
pubmed: 35444643
Am J Respir Crit Care Med. 2004 Nov 1;170(9):1000-5
pubmed: 15271694
J Biomed Sci. 2013 May 01;20:26
pubmed: 23634990
Inflamm Res. 2000 Feb;49(2):73-9
pubmed: 10738945
Br J Pharmacol. 2007 Jul;151(5):571-9
pubmed: 17471177
Mol Immunol. 2019 Aug;112:291-304
pubmed: 31228661
Am J Respir Cell Mol Biol. 2006 Apr;34(4):399-409
pubmed: 16340000
Methods Mol Biol. 2022;2406:113-130
pubmed: 35089553
Respir Med. 2012 Dec;106(12):1680-9
pubmed: 22981321
J Immunol. 2016 Jul 15;197(2):590-8
pubmed: 27271568
Science. 2017 Jun 9;356(6342):1076-1080
pubmed: 28495878
Front Pharmacol. 2018 Feb 01;9:39
pubmed: 29449813
Biophys J. 2011 Jan 5;100(1):108-16
pubmed: 21190662
Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L881-L892
pubmed: 27612964
Am J Respir Cell Mol Biol. 2014 Nov;51(5):604-14
pubmed: 24960334
J Immunol. 1998 Feb 15;160(4):1920-8
pubmed: 9469454
Crit Rev Microbiol. 2021 Mar;47(2):192-205
pubmed: 33455514
Oncotarget. 2017 May 13;8(47):81813-81824
pubmed: 29137224
Proteins. 2012 Feb;80(2):374-81
pubmed: 22095872
J Biol Chem. 1992 Feb 5;267(4):2664-70
pubmed: 1733963
J Biol Chem. 1998 Dec 11;273(50):33115-8
pubmed: 9837875
J Biol Chem. 2003 Oct 31;278(44):43254-60
pubmed: 12913002
Biochim Biophys Acta. 2012 Nov;1818(11):2550-62
pubmed: 22659676
Infect Immun. 1989 Feb;57(2):546-52
pubmed: 2643575
Int J Mol Sci. 2021 Oct 15;22(20):
pubmed: 34681806
J Gen Virol. 2013 Jan;94(Pt 1):40-49
pubmed: 23052388
Colloids Surf B Biointerfaces. 2022 Feb;210:112237
pubmed: 34836708
Biochem J. 1996 Jan 15;313 ( Pt 2):683-9
pubmed: 8573110
Nat Commun. 2017 May 23;8:15504
pubmed: 28534479
Biochim Biophys Acta. 2016 Mar;1858(3):546-66
pubmed: 26556394
Int Immunopharmacol. 2017 Aug;49:6-12
pubmed: 28549244
Biochemistry. 2000 May 30;39(21):6529-37
pubmed: 10828969
Biochem J. 2005 Oct 1;391(Pt 1):115-24
pubmed: 15932345
Pediatr Pathol Mol Med. 2001 Jul-Aug;20(4):249-68
pubmed: 11486733
J Immunol. 2004 Apr 15;172(8):4987-94
pubmed: 15067080
Nature. 2000 Aug 31;406(6799):959-64
pubmed: 10984043
Elife. 2017 Sep 18;6:
pubmed: 28920575
J Allergy Clin Immunol. 2006 Jun;117(6):1328-35
pubmed: 16750994
J Biol Chem. 2008 Nov 7;283(45):30471-81
pubmed: 18765670
Nat Rev Immunol. 2016 May;16(5):321-34
pubmed: 27087664
Front Med (Lausanne). 2020 Sep 18;7:554
pubmed: 33043031
Nat Rev Drug Discov. 2020 May;19(5):311-332
pubmed: 32107480
J Biol Chem. 1998 Feb 6;273(6):3718-24
pubmed: 9452503
Am J Respir Cell Mol Biol. 2011 Mar;44(3):423-9
pubmed: 20508069
J Innate Immun. 2013;5(3):251-60
pubmed: 23235402
Biochem J. 1999 Aug 1;341 ( Pt 3):501-13
pubmed: 10417311
J Dermatol Sci. 2005 Nov;40(2):123-32
pubmed: 15963694
J Biol Chem. 1998 Jun 12;273(24):15183-91
pubmed: 9614132
Sci Rep. 2019 Mar 18;9(1):4780
pubmed: 30886247
J Biol Chem. 2012 Apr 27;287(18):15034-43
pubmed: 22418431
J Immunol. 2015 Aug 15;195(4):1628-36
pubmed: 26163587
J Immunol. 2009 Jul 1;183(1):543-51
pubmed: 19542465
J Biol Chem. 2005 Mar 4;280(9):7659-70
pubmed: 15615713
Biochim Biophys Acta. 2006 Sep;1758(9):1408-25
pubmed: 16716248
Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L799-805
pubmed: 11053013
Front Immunol. 2022 May 12;13:880961
pubmed: 35634307
J Biol Chem. 1994 Jan 21;269(3):2241-4
pubmed: 8294481
Vaccines (Basel). 2018 Sep 14;6(3):
pubmed: 30223448
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):
pubmed: 34183393
Physiol Rev. 1997 Oct;77(4):931-62
pubmed: 9354809
Microbiol Mol Biol Rev. 2016 Jun 15;80(3):629-61
pubmed: 27307579
Biochem J. 2014 Jan 15;457(2):263-75
pubmed: 24117320
Front Immunol. 2018 Sep 04;9:1998
pubmed: 30233589
J Immunol. 2013 Dec 1;191(11):5714-21
pubmed: 24174616
Biomater Adv. 2022 Mar;134:112551
pubmed: 35513950
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9541-6
pubmed: 9689116
Biochem J. 1993 Dec 15;296 ( Pt 3):585-93
pubmed: 8280055
Biochemistry. 2002 Nov 26;41(47):14041-53
pubmed: 12437362
Pulm Pharmacol Ther. 2005;18(5):321-7
pubmed: 15939310
Eur Respir J. 2017 Mar 15;49(3):
pubmed: 28298400

Auteurs

Lidia de Tapia (L)

Department of Biochemistry and Molecular Biology, Complutense University of Madrid, Madrid, Spain.

Belén García-Fojeda (B)

Department of Biochemistry and Molecular Biology, Complutense University of Madrid, Madrid, Spain.

Nina Kronqvist (N)

Department of Biosciences and Nutrition, Neo, Karolinska Institutet, Huddinge, Sweden.

Jan Johansson (J)

Department of Biosciences and Nutrition, Neo, Karolinska Institutet, Huddinge, Sweden.

Cristina Casals (C)

Department of Biochemistry and Molecular Biology, Complutense University of Madrid, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH